Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and Osimertinib

被引：0
|
作者：
Spira, Alexander I.
Berz, David
Jotte, Robert M.
Pachipala, Krishna K.
Berger, Mark S.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A065
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).
    Berz, David
    Jotte, Robert M.
    Pachipala, Krishna Kishore
    Spira, Alexander I.
    Berger, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Design of a dose escalation phase 1/2 trial for a novel combined cell and oncolytic viral therapy
    Contag, Pamela R.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
    Starodub, A. N.
    Kim, S-B.
    Davar, D.
    Powderly, J.
    Hill, A. G.
    Yeku, O.
    Gabrail, N.
    Krapp, C.
    Pihl, S.
    Chen, M.
    Slavsky, S.
    Castro, D. Torrejon
    Singel, S. M.
    Kwatra, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S628 - S628
  • [4] Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 b/g alone or in combination with pembrolizumab: Initial results from dose escalation
    Starodub, Alexander
    Powderly, John D.
    Kim, Sung-Bae
    Davar, Diwakar
    Hill, Andrew Graham
    Yeku, Oladapo O.
    Gabrail, Nashat Y.
    Krapp, Christian
    Pihl, Susanne
    Zhang, Ying
    Slavsky, Sibel
    Castro, Davis Y. Torrejon
    Uyei, Anne
    Singel, Stina Mui
    Kwatra, Vineet
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Retinal Gene Therapy for Choroideremia in a Multicenter Dose Escalation Phase I/II Clinical Trial
    MacLaren, Robert E.
    Xue, Kanmin
    Barnard, Alun R.
    Patricio, Maria Ines
    Edwards, Thomas L.
    Downes, Susan
    Lotery, Andrew
    Black, Graeme
    Webster, Andrew
    Jolly, Jasleen K.
    Seabra, Miguel C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [6] GENE THERAPY FOR CRIGLER NAJJAR SYNDROME: RESULTS OF THE DOSE ESCALATION PHASE OF THE CARECN CLINICAL TRIAL
    D'Antiga, Lorenzo
    Beuers, Ulrich
    Brunetti-Pierri, Nicola
    Baumann, Ulrich
    Di Giorgio, Angelo
    Aronson, Sem
    Hubert, Aurelie
    Romano, Roberta
    Junge, Norman
    Bosma, Piter J.
    Bortolussi, Giulia
    Muro, Andres
    Pavlyuk, Mariya
    Veron, Philippe
    Ronzitti, Giuseppe
    Collaud, Fanny
    Knuchel-Legendre, Nathalie
    Mingozzi, Federico
    Labrune, Philippe
    HEPATOLOGY, 2021, 74 (06) : 1406A - 1407A
  • [7] Review of dose escalation scheme in oncologic phase I studies of gene therapy: Does it work?
    Nagamura, F
    Tojo, A
    Asano, S
    BLOOD, 2003, 102 (11) : 502B - 502B
  • [8] Factors Influencing Time to Determination of the Recommended Phase 2 Dose in Phase 1 Clinical Trials
    Caldwell, Samantha
    Sima, Chao
    Jameson, Gayle
    Fleck, Sharon
    Weiss, Glen J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (02): : 146 - 150
  • [9] MSC BASED THERAPY FOR SEVERE OSTEOARTHRITIS OF THE KNEE. A PHASE 1 DOSE ESCALATION TRIAL
    Jorgensen, C.
    Noeth, U.
    Facchini, A.
    Barry, F.
    Sensebe, L.
    Casteilla, L.
    Noel, D.
    Lisignoli, G.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S442 - S442
  • [10] Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma
    Sundahl, Nora
    De Wolf, Katrien
    Kruse, Vibeke
    Meireson, Annabel
    Reynders, Dries
    Goetghebeur, Els
    Van Gele, Mireille
    Speeckaert, Reinhart
    Hennart, Benjamin
    Brochez, Lieve
    Ost, Piet
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (04): : 906 - 915
12345